Gilead Sciences (GILD) Operating Income (2009 - 2026)

Gilead Sciences (GILD) has reported Operating Income for 18 consecutive years, with $2.6 billion the latest figure, recorded in Q1 2026.

• Operating Income for Q1 2026 came in at $2.6 billion, up 15.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.4 billion (up 26.15% YoY), and the FY2025 annual result was $10.0 billion, up 503.01% from the prior year.
• Operating Income was $2.6 billion for Q1 2026 at Gilead Sciences, up from $2.0 billion in the prior quarter.
• Over five years, Operating Income peaked at $3.3 billion in Q3 2025 and troughed at -$4.3 billion in Q1 2024.
• Average Operating Income over 5 years is $1.7 billion, with a median of $2.2 billion recorded in 2025.
• Year-over-year, Operating Income surged 765.48% in 2023 and slumped 353.49% in 2024.
• Over 5 years, Operating Income stood at $2.3 billion in 2022, then fell by 28.89% to $1.6 billion in 2023, then soared by 52.11% to $2.5 billion in 2024, then slipped by 19.09% to $2.0 billion in 2025, then jumped by 30.34% to $2.6 billion in 2026.
• Per Business Quant data, the three most recent Operating Income figures were $2.6 billion in Q1 2026, $2.0 billion in Q4 2025, and $3.3 billion in Q3 2025.